|
Generic Equivalent to Zyrtec(r) Allergy Tablets and Zyrtec(r) Hives Relief Tablets
HAWTHORNE, NY, USA | July 27, 2009 | Taro Pharmaceutical Industries Ltd. ("Taro," the "Company,") (Pink Sheets:TAROF) reported today that it has received approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for cetirizine hydrochloride tablets (OTC), 5 mg and 10 mg ("Cetirizine Tablets"). The product will be marketed by Taro's U.S. affiliate, Taro Pharmaceuticals U.S.A., Inc.
Taro's Cetirizine Tablets are bioequivalent to McNeil Consumer Healthcare's Zyrtec(r) Allergy Tablets, 5 mg and 10 mg and Zyrtec(r) Hives Relief Tablets, 5 mg and 10 mg. Taro previously received approval for cetirizine hydrochloride oral solution in April 2008.
Cetirizine Tablets are a nonprescription drug approved for the temporary relief of symptoms due to hay fever or other respiratory allergies (sneezing; runny nose; itchy, watery eyes; itchy throat or nose) in adults and children 2 years of age and older. Cetirizine Tablets are also approved for the relief of itching due to hives in adults and children 6 years of age and older.
According to industry sources, annual U.S. sales of this product are approximately $350 million.
Taro is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products.
SOURCE: Taro Pharmaceutical Industries Ltd |
